Assessment of the risk for developing a second malignancy from scattered and secondary radiation in radiation therapy

Health Physics

Volumn 103, Issue 5, 2012, Pages 652-661

  Paganetti, Harald ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

medical radiation; National Council on Radiation Protection and Measurements; radiation damage; risk estimates

Indexed keywords

ARTICLE; HUMAN; METHODOLOGY; RADIATION INDUCED NEOPLASM; RADIATION SCATTERING; RADIOTHERAPY; RISK ASSESSMENT; SECOND CANCER; STATISTICAL MODEL;

HUMANS; MODELS, STATISTICAL; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RADIOTHERAPY; RISK ASSESSMENT; SCATTERING, RADIATION;

EID: 84867175849     PISSN: 00179078     EISSN: None     Source Type: Journal    
DOI: 10.1097/HP.0b013e318261113d     Document Type: Article

References (96)

1. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 174:840-850; 2010.
2. Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, Neglia JP, Stovall M, Srivastava D, Robison LL. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 29:3056-3064; 2011.
3. Athar BS, Paganetti H. Neutron equivalent doses and associated lifetime cancer incidence risks for head and neck and spinal proton therapy. Phys Med Biol 54:4907-4926; 2009.
4. Athar BS, Paganetti H. Comparison of second cancer risk due to out-of-field doses from 6-MV IMRT and proton therapy based on 6 pediatric patient treatment plans. Radiother Oncol 98:87-92; 2011.
5. Athar BS, Bednarz B, Seco J, Hancox C, Paganetti H. Comparison of out-of-field photon doses in 6-MV IMRTand neutron doses in proton therapy for adult and pediatric patients. Phys Med Biol 55:2879-2892; 2010.
6. Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, RonckersCM, Friedman DL, Stovall M, Yasui YY, Robison LL, Meadows AT, Kadan-Lottick NS. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24: 476-483; 2006.
7. Bhatia S, Landier W. Evaluating survivors of pediatric cancer. Cancer J 11:340-354; 2005.
8. Biological Effects of Ionizing Radiation. Health risks from exposure to low levels of ionizing radiation, BEIRVII, Phase 2. Washington DC: National Research Council, National Academy of Science 2006.
9. Blettner M, Boice JD Jr. Radiation dose and leukaemia risk: general relative risk techniques for dose-response models in a matched case-control study. Stat Med 10:1511-1526; 1991.
10. Boice JD Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET, Latourette HB, Peters LJ, Schulz MD, Lundell M, Pettersson F, Storm HH, Bell CMJ, Coleman MP, Fraser P, Palmer M, Prior P, Choi NW, Hislop TG, Koch M, Robb D, Robson D, Spengler RF, von Fournier D, Frischkorn R, Lochmuller H, Pompe-Kirn V, Rimpela A, Kjorstad K, Pejovic MH, Sigurdsson K, Pisani P, Kucera H, Hutchison GB. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 79:1295-1311; 1987.
11. Brenner DJ. Extrapolating radiation-induced cancer risks from low doses to very low doses. Health Phys 97:505-509; 2009.
12. Brenner DJ, Hall EJ. Secondary neutrons in clinical proton radiotherapy: a charged issue. Radiother Oncol 86:165-170; 2008.
13. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, Ron E, Sachs RK, Samet JM, Setlow RB, Zaider M. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci USA 100:13761-13766; 2003.
14. Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, Andersson M, Fossa SD, Joensuu H, Boice JD, Kleinerman RA, Travis LB. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 99:1634-1643; 2007.
15. Clasie B, Wroe A, Kooy H, Depauw N, Flanz J, Paganetti H, Rosenfeld A. Assessment of out-of-field absorbed dose and equivalent dose in proton fields. Med Phys 37:311-321; 2010.
16. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Holowaty E, Karjalainen S, Langmark F, Nasca PC, Schwartz AG, Schymura MJ, Storm HH, Toogood P, Weyer P, Moloney WC. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 86:1315-1324; 1994.
17. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM,Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boice JD Jr. Solid cancers after bone marrow transplantation. N Engl J Med 336:897-904; 1997.
18. Dennis JA. The relative biological effectiveness of neutron radiation and its implications for quality factor and dose limitation. Progress Nucl Energy 20:133-149; 1987.
19. Diallo I, Haddy N, Adjadj E, Samand A, Quiniou E, Chavaudra J, Alziar I, Perret N, Guerin S, Lefkopoulos D, de Vathaire F. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 74: 876-883; 2009.
20. DoerrW, Herrmann T. Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. Strahlenther Onkol 178:357-362; 2002.
21. Edwards AA, Neutron RBE. values and their relationship to judgments in radiological protection. JRadiol Prot 19:93-105; 1999.
22. Fontenot J, Taddei P, Zheng Y, Mirkovic D, Jordan T, Newhauser W. Equivalent dose and effective dose from stray radiation during passively scattered proton radiotherapy for prostate cancer. Phys Med Biol 53:1677-1688; 2008.
23. Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity-modulated X-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys 74:616-622; 2009.
24. Foss Abrahamsen A, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaloy S. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 13: 1786-1791; 2002.
25. Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van't Veer MB, Fraumeni JF, Boice JD, Jr, Clarke EA, Travis LB. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 159:161-173; 2003.
26. Hecksel D, Anferov V, Fitzek M, Shahnazi K. Influence of beam efficiency through the patient-specific collimator on secondary neutron dose equivalent in double scattering and uniform scanning modes of proton therapy. Med Phys 37: 2910-2917; 2010.
27. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. New York: Elsevier; ICRP Publication 60; 1991.
28. International Commission on Radiological Protection. Relative Biological Effectiveness (RBE), QualityFactor (Q), and Radiation Weighting Factor (wR). New York: Elsevier; ICRP Publication 92 2003.
29. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection. New York: Elsevier; ICRP Publication 103; 2007.
30. Imaizumi M, Usa T, Tominaga T, Neriishi K, Akahoshi M, Nakashima E, Ashizawa K, Hida A, Soda M, Fujiwara S, YamadaM,Ejima E,YokoyamaN,OkuboM,Sugino K, Suzuki G, Maeda R, Nagataki S, Eguchi K. Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. JAMA 295: 1011-1022; 2006.
31. Jiang H, Wang B, Xu XG, Suit HD, Paganetti H. Simulation of organ specific patient effective dose due to secondary neutrons in proton radiation treatment. Phys Med Biol 50: 4337-4353; 2005.
32. Kellerer AM, Nekolla EA, Walsh L. On the conversion of solid cancer excess relative risk into lifetime attributable risk. Radiat Environ Biophys 40:249-257; 2001.
33. Kellerer AM, RuhmW,Walsh L. Indications of the neutron effect contribution in the solid cancer data of the A-bomb survivors. Health Phys 90:554-564; 2006.
34. Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, Meadows AT, Friedman D, Robison LL, Diller L. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 141:590-597; 2004.
35. Klein EE, Maserang B, Wood R, Mansur D. Peripheral doses from pediatric IMRT. Med Phys 33:2525-2531; 2006.
36. Kocher DC, Apostoaei AI, Hoffman FO. Radiation effectiveness factors for use in calculating probability of causation of radiogenic cancers. Health Phys 89:3-32; 2005.
37. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys 68:1265-1271; 2007.
38. Kuttesch JF Jr, Wexler LH, Marcus RB, Fairclough D, Weaver-McClure L, White M, Mao L, Delaney TF, Pratt CB, Horowitz ME, Kun LE. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clinical Oncol 14:2818-2825; 1996.
39. Little MP. Estimates of neutron relative biological effectiveness derived from the Japanese atomic bomb survivors. Int J Radiat Biol 72:715-726; 1997.
40. Little MP. A comparison of the degree of curvature in the cancer incidence dose-response in Japanese atomic bomb survivors with that in chromosome aberrations measured in vitro. Int J Radiat Biol 76:1365-1375; 2000.
41. Little MP. Comparison of the risks of cancer incidence and mortality following radiation therapy for benign and malignant disease with the cancer risks observed in the Japanese A-bomb survivors. Intl J Radiat Biol 77:431-464; 2001.
42. Lomax AJ, Bortfeld T, Goitein G, Debus J, Dykstra C, Tercier P-A, Coucke PA, Mirimanoff RO. A treatment planning intercomparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 51:257-271; 1999.
43. Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27:2356-2362; 2009.
44. Merchant TE, Hua CH, Shukla H, Ying X, Nill S, Oelfke U. Proton versus photon radiotherapy for common pediatric brain tumors: comparison of models of dose characteristics and their relationship to cognitive function. Pediatr Blood Cancer 51: 110-117; 2008.
45. Mesoloras G, Sandison GA, Stewart RD, Farr JB, Hsi WC. Neutron scattered dose equivalent to a fetus from proton radiotherapy of the mother. Med Phys 33:2479-2490; 2006.
46. Minniti G, Traish D, Ashley S, Gonsalves A, Brada M. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab 90:800-804; 2005.
47. Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Intl J Radiat Oncol Biol Phys 54:824-829; 2002.
48. Moyers MF, Benton ER, Ghebremedhin A, Coutrakon G. Leakage and scatter radiation from a double scattering based proton beamline. Med Phys 35:128-144; 2008.
49. Mullenders L, Atkinson M, Paretzke H, Sabatier L, Bouffler S. Assessing cancer risks of low-dose radiation. Nat Rev Cancer 9:596-604; 2009.
50. National Council on Radiation Protection and Measurements. The relative biological effectiveness of radiations of different quality. Bethesda, MD: NCRP Report No. 104; 1990.
51. National Council on Radiation Protection and Measurements. Uncertainties in fatal cancer risk estimates used in radiation protection. Bethesda, MD: NCRP Report No. 126; 1997.
52. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 93: 618-629; 2001.
53. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98: 1528-1537; 2006.
54. Newhauser WD, Fontenot JD, Mahajan A, Kornguth D, Stovall M, Zheng Y, Taddei PJ, Mirkovic D, Mohan R, Cox JD, Woo S. The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys Med Biol 54: 2277-2291; 2009.
55. Paganetti H, Gerweck LE, Goitein M. The general relation between tissue response to x-radiation (a/b-values) and the relative biological effectineness (RBE) of protons: prediction by the Katz track-structure model. Intl J Radiat Biol 76: 985-998; 2000.
56. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Loeffler JS, Goitein M, Suit HD. Relative biological effectiveness (RBE) values for proton beam therapy. Intl J Radiat Oncol Biol Phys 53:407-421; 2002.
57. Palm A, Johansson KA. A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors. Acta Oncol 46: 462-473; 2007.
58. Perez-Andujar A, Newhauser WD, Deluca PM. Neutron production from beam-modifying devices in a modern double scattering proton therapy beam delivery system. Phys Med Biol 54:993-1008; 2009.
59. Pierce DA, Shimizu Y, Preston DL, Vaeth M, Mabuchi K. Studies of the mortality of atomic bomb survivors. Report 12, Part I. Cancer: 1950-1990. Radiat Res 146:1-27; 1996.
60. Polf JC, Newhauser WD. Calculations of neutron dose equivalent exposures from range-modulated proton therapy beams. Phys Med Biol 50:3859-3873; 2005.
61. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 160:381-407; 2003.
62. Preston DL, Pierce DA, Shimizu Y, Cullings HM, Fujita S, Funamoto S, Kodama K. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 162:377-389; 2004.
63. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 168:1-64; 2007.
64. Ron E. Childhood cancerVtreatment at a cost. J Natl Cancer Inst 98:1510-1511; 2006.
65. Ron E, Modan B, Boice JD, Alfandary E, Stovall M, Chetrit A, Katz L. Tumors of the brain and nervous system after radiotherapy in childhood. N Eng J Med 319:1033-1039; 1988.
66. Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Mertens AC, Liu Y, Hammond S, Land CE, Neglia JP, Donaldson SS, Meadows AT, Sklar CA, Robison LL, Inskip PD. Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. Radiat Res 166: 618-628; 2006.
67. Rubino C, Shamsaldin A, Le MG, Labbe M, Guinebretiere JM, Chavaudra J, de Vathaire F. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 89:277-288; 2005.
68. Sachs RK, Brenner DJ. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 102: 13040-13045; 2005.
69. Schneider U. Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula. Med Phys 36:1138-1143; 2009.
70. Schneider U, Kaser-Hotz B. Radiation risk estimates after radiotherapy: application of the organ equivalent dose concept to plateau dose-response relationships. Radiat Environ Biophys 44:235-239; 2005a.
71. Schneider U, Kaser-Hotz B. A simple dose-response relationship for modeling secondary cancer incidence after radiotherapy. Z Med Phys 15:31-37; 2005b.
72. Schneider U, Walsh L. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys 47: 253-263; 2008.
73. Schneider U, Agosteo S, Pedroni E, Besserer J. Secondary neutron dose during proton therapy using spot scanning. Intl J Radiat Oncol Biol Phys 53:244-251; 2002.
74. Schneider U, Zwahlen D, Ross D, Kaser-Hotz B. Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose. Int J Radiat Oncol Biol Phys 61:1510-1515; 2005.
75. Schneider U, Lomax A, Timmermann B. Second cancers in children treated with modern radiotherapy techniques. Radiother Oncol 89:135-140; 2008.
76. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 365: 2014-2023; 2005.
77. Suit H, Goldberg S, Niemierko A, Ancukiewicz M, Hall E, Goitein M, Wong W, Paganetti H. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res 167:12-42; 2007.
78. Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng Y, Kornguth D, Mohan R, Newhauser WD. Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys Med Biol 54: 2259-2275; 2009.
79. Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, NewtonW, Hoover RN, Fraumeni JF Jr. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317:588-593; 1987.
80. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. NewYork: UNSCEAR; Report to the General Assembly, with scientific annexes. Vol. I: Report to the General Assembly, Scientific Annexes A and B; 2006a.
81. United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation. NewYork: UNSCEAR; Report to the General Assembly, with scientific annexes. Vol. II: Scientific Annexes C, D and E; 2006b.
82. U.S. Environmental Protection Agency. Estimating radiogenic cancer risks. Addendum: Uncertainty analysis. Washington, DC: U.S. EPA; EPA 402-R-99-003, 1999.
83. Upton AC. Radiation hormesis: data and interpretations. Crit Rev Toxicol 31:681-695; 2001.
84. WalshL,RuehmW,KellererAM.Cancer risk estimates for gammarays with regard to organ-specific doses. Part I: all solid cancers combined. Radiat Environmental Biophys 43:145-151; 2004a.
85. Walsh L, Ruehm W, Kellerer AM. Cancer risk estimates for gamma-rays with regard to organ-specific doses. Part II: sitespecific solid cancers. Radiat Environmental Biophys 43: 225-231; 2004b.
86. Wroe A, Rosenfeld A, Schulte R. Out-of-field dose equivalents delivered by proton therapy of prostate cancer. Med Phys 34:3449-3456; 2007.
87. Wroe A, Clasie B, Kooy H, Flanz J, Schulte R, Rosenfeld A. Out-of-field dose equivalents delivered by passively scattered therapeutic proton beams for clinically relevant field configurations. Int J Radiat Oncol Biol Phys 73:306-313; 2009.
88. Xu XG, Eckerman KF. Handbook of anatomical models for radiation dosimetry (series in medical physics and biomedical engineering). Boca Raton, FL: CRC Press, Taylor and Francis; 2009.
89. Xu XG, Paganetti H. Better radiation weighting factors for neutrons generated from proton treatment are needed. Radiat Protect Dosim 138:291-294; 2010.
90. Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol 53:R193YR241; 2008.
91. Yan X, Titt U, Koehler AM, Newhauser WD. Measurement of neutron dose equivalent to proton therapy patients outside of the proton radiation field. Nucl Instru Methods Phys Research A 476:429-434; 2002.
92. Yonai S, MatsufujiN, Kanai T, MatsuiY, Matsushita K,Yamashita H, Numano M, Sakae T, Terunuma T, Nishio T, Kohno R, Akagi T. Measurement of neutron ambient dose equivalent in passive carbon-ion and proton radiotherapies. Med Phys 35: 4782-4792; 2008.
93. Zacharatou Jarlskog C, Paganetti H. The risk of developing second cancer due to neutron dose in proton therapy as a function of field characteristics, organ, and patient age. Intl J Radiat Oncol Biol Phys 72:228-235; 2008.
94. Zacharatou Jarlskog C, Lee C, Bolch W, Xu XG, Paganetti H. Assessment of organ specific neutron doses in proton therapy using whole-body age-dependent voxel phantoms. Phys Med Biol 53:693-714; 2008.
95. Zaider M. Evidence of a neutron RBE of 70 (T50) for solid-tumor induction at Hiroshima and Nagasaki and its implications for assessing the effective neutron quality factor. Health Phys 61: 631-636; 1991.
96. Zheng Y, Newhauser W, Fontenot J, Taddei P, Mohan R. Monte Carlo study of neutron dose equivalent during passive scattering proton therapy. Phys Med Biol 52:4481-4496; 2007.